Tandutinib (BioDeep_00000184135)

   

human metabolite blood metabolite


代谢物信息卡片


4-{6-methoxy-7-[3-(piperidin-1-yl)propoxy]quinazolin-4-yl}-N-[4-(propan-2-yloxy)phenyl]piperazine-1-carboxamide

化学式: C31H42N6O4 (562.3267)
中文名称: 坦度替尼
谱图信息: 最多检出来源 Homo sapiens(blood) 100%

分子结构信息

SMILES: CC(C)OC1=CC=C(C=C1)NC(=O)N2CCN(CC2)C3=NC=NC4=CC(=C(C=C43)OC)OCCCN5CCCCC5
InChI: InChI=1S/C31H42N6O4/c1-23(2)41-25-10-8-24(9-11-25)34-31(38)37-17-15-36(16-18-37)30-26-20-28(39-3)29(21-27(26)32-22-33-30)40-19-7-14-35-12-5-4-6-13-35/h8-11,20-23H,4-7,12-19H2,1-3H3,(H,34,38)

描述信息

C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor
C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor

同义名列表

12 个代谢物同义名

4-{6-methoxy-7-[3-(piperidin-1-yl)propoxy]quinazolin-4-yl}-N-[4-(propan-2-yloxy)phenyl]piperazine-1-carboxamide; 4-(6-Methoxy-7-(3-piperidin-1-ylpropoxy)quinazolin-4-yl)piperazine-1-carboxylic acid (4-isopropoxyphenyl)amide; (4-(6-Methoxy-7-(3-piperidylpropoxy)quinazolin-4-yl)piperazinyl)-N-(4-(methylethoxy)phenyl)carboxamide; Tandutinib (MLN518); Tandutinibum; Tandutinib; CT-53518; CT 53518; MLN-518; CT53518; MLN 518; MLN518



数据库引用编号

8 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。

亚细胞结构定位 关联基因列表


文献列表

  • Haleema Sadia Malik, Aishah Bilal, Rahim Ullah, Maheen Iqbal, Sardraz Khan, Ishtiaq Ahmed, Karsten Krohn, Rahman Shah Zaib Saleem, Hidayat Hussain, Amir Faisal. Natural and Semisynthetic Chalcones as Dual FLT3 and Microtubule Polymerization Inhibitors. Journal of natural products. 2020 10; 83(10):3111-3121. doi: 10.1021/acs.jnatprod.0c00699. [PMID: 32975953]
  • Tracy T Batchelor, Elizabeth R Gerstner, Xiaobu Ye, Serena Desideri, Daniel G Duda, David Peereboom, Glenn J Lesser, Sajeel Chowdhary, Patrick Y Wen, Stuart Grossman, Jeffrey G Supko. Feasibility, phase I, and phase II studies of tandutinib, an oral platelet-derived growth factor receptor-β tyrosine kinase inhibitor, in patients with recurrent glioblastoma. Neuro-oncology. 2017 04; 19(4):567-575. doi: 10.1093/neuonc/now185. [PMID: 27663390]
  • Adam del Corral, Catherine Dutreix, Alice Huntsman-Labed, Sebastien Lorenzo, Joel Morganroth, Robert Harrell, Yanfeng Wang. Midostaurin does not prolong cardiac repolarization defined in a thorough electrocardiogram trial in healthy volunteers. Cancer chemotherapy and pharmacology. 2012 May; 69(5):1255-63. doi: 10.1007/s00280-012-1825-y. [PMID: 22294470]
  • Marek Dziadosz, Rüdiger Lessig, Heidemarie Bartels. HPLC-DAD protein kinase inhibitor analysis in human serum. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2012 Apr; 893-894(?):77-81. doi: 10.1016/j.jchromb.2012.02.037. [PMID: 22425385]
  • Dale R Shepard, Matthew M Cooney, Paul Elson, Ronald M Bukowski, Robert Dreicer, Brian I Rini, Jorge A Garcia. A phase II study of tandutinib (MLN518), a selective inhibitor of type III tyrosine receptor kinases, in patients with metastatic renal cell carcinoma. Investigational new drugs. 2012 Feb; 30(1):364-7. doi: 10.1007/s10637-010-9516-1. [PMID: 20711630]
  • David K Heidary, George Huang, Diane Boucher, Jianguo Ma, Cornelia Forster, Ron Grey, Jinwang Xu, Michael Arnost, Deborah Choquette, Guanjing Chen, Jie-Hua Zhou, Yung-Mae Yao, Edward D Ball, Mark Namchuk, Robert J Davies, Greg Henkel. VX-322: a novel dual receptor tyrosine kinase inhibitor for the treatment of acute myelogenous leukemia. Journal of medicinal chemistry. 2012 Jan; 55(2):725-34. doi: 10.1021/jm201198w. [PMID: 22221201]
  • Paul Mathew, Nizar Tannir, Shi-Ming Tu, Sijin Wen, Charles C Guo, Valerie Marcott, Benjamin Nebiyou Bekele, Lance Pagliaro. Accelerated disease progression in prostate cancer and bone metastases with platelet-derived growth factor receptor inhibition: observations with tandutinib. Cancer chemotherapy and pharmacology. 2011 Oct; 68(4):889-96. doi: 10.1007/s00280-011-1567-2. [PMID: 21290244]
  • Johnny J Yang, Mark N Milton, Shaoxia Yu, Mingxiang Liao, Ning Liu, Jing-Tao Wu, Liangshang Gan, Suresh K Balani, Frank W Lee, Shimoga Prakash, Cindy Q Xia. P-glycoprotein and breast cancer resistance protein affect disposition of tandutinib, a tyrosine kinase inhibitor. Drug metabolism letters. 2010 Dec; 4(4):201-12. doi: 10.2174/187231210792928279. [PMID: 20670210]
  • Daniel J DeAngelo, Richard M Stone, Mark L Heaney, Stephen D Nimer, Ronald L Paquette, Rebecca B Klisovic, Michael A Caligiuri, Michael R Cooper, Jean-Michel Lecerf, Michael D Karol, Shihong Sheng, Nick Holford, Peter T Curtin, Brian J Druker, Michael C Heinrich. Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics. Blood. 2006 Dec; 108(12):3674-81. doi: 10.1182/blood-2006-02-005702. [PMID: 16902153]
  • Anjali Pandey, Deborah L Volkots, Joseph M Seroogy, Jack W Rose, Jin-Chen Yu, Joseph L Lambing, Athiwat Hutchaleelaha, Stanley J Hollenbach, Keith Abe, Neill A Giese, Robert M Scarborough. Identification of orally active, potent, and selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family. Journal of medicinal chemistry. 2002 Aug; 45(17):3772-93. doi: 10.1021/jm020143r. [PMID: 12166950]